title: Mirabegron in the treatment of overactive bladder.
abstract: BACKGROUND
  Mirabegron is a selective β3-adrenergic receptor agonist recently developed for the treatment of patients with overactive bladder (OAB), which offers an alternative pharmacological option to the well-established treatment with antimuscarinics (AMs).
  
  
  METHODS
  This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of mirabegron and gives readers a complete overview of Phase II and III studies on the clinical efficacy, tolerability and safety of this agent in the setting of OAB treatment.
  
  
  CONCLUSIONS
  Both Phase II and III trials have shown that mirabegron is efficacious and safe in treating patients with OAB. Future research should focus on the assessment of mirabegron concentrations in the CNS and on the evaluation of the potential of the combination of mirabegron with AMs. Another field for future research is represented by the investigation of the interaction of mirabegron with CYP2D6 inhibitors. Furthermore, current literature completely lacks studies on the efficacy and safety of mirabegron in the pediatric population and such trials are awaited.
authors.affiliation: IRRCS San Raffaele Hospital and Vita-Salute San Raffaele University, Via Olgettina 58-60, 20132 , Milan , Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Leone Roberti Maggiore
authors.forename: Linda
authors.initials: L
authors.lastname: Cardozo
authors.forename: Simone
authors.initials: S
authors.lastname: Ferrero
authors.forename: Filomena
authors.initials: F
authors.lastname: Sileo
authors.forename: Alice
authors.initials: A
authors.lastname: Cola
authors.forename: Fabio
authors.initials: F
authors.lastname: Del Deo
authors.forename: Marco
authors.initials: M
authors.lastname: Torella
authors.forename: Nicola
authors.initials: N
authors.lastname: Colacurci
authors.forename: Massimo
authors.initials: M
authors.lastname: Candiani
authors.forename: Stefano
authors.initials: S
authors.lastname: Salvatore
mesh_terms: D000083:Acetanilides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013844:Thiazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D000083:Acetanilides; D018727:Muscarinic Antagonists; D013844:Thiazoles; C520025:mirabegron